Fate Therapeutics (FATE) Misses Q1 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.30), $0.06 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.63 million versus the consensus estimate of $2.37 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Walmart shares fall despite earnings beat
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance